Dr. Sophie Kornowski
Dr. Kornowski and her team completed over 50 deals per year in her role as head of partnering at Roche. Previously, she led Roche’s major affiliate for five years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the United States, France and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the United States. Dr. Kornowski has an MBA from the University of Chicago Booth and a PhD in Pharmacy from Paris Descartes University.
Peter D. Staple, President and Chief Executive Officer
Prior to joining ALZA, Mr. Staple served in senior positions at Cetus and Chiron Corporations, where his responsibilities covered corporate partnering, licensing, mergers and acquisitions, and financings, including transactions involving commercialization of polymerase chain reaction, hepatitis C and HIV screening technologies. Prior to entering the biotechnology industry, Mr. Staple practiced corporate and securities law with Heller Ehrman LLP. Mr. Staple serves on the board of directors of Depomed, Inc., and has served multiple terms on the board of visitors at Stanford Law School. He holds B.A. and J.D. degrees from Stanford University.
Christopher A. Viehbacher
Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario.
Mr. Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Legion d’Honneur.
Mr. Wilson has extensive experience in biotechnology and venture investing, leading transactions from seed-investments to near commercial assets. For more than a decade, he was a member of the life science investment team at the Morningside Group, a privately-held investment firm. With Morningside, he assisted with multiple financings, including several public and private companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO) and Argos (NASDAQ: ARGS).
Mr. Wilson also served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy and ophthalmology. He has lectured extensively on life science investing and management, and is a long-time supporter of patient-advocacy groups. Mr. Wilson holds a law degree and a chemical engineering degree, both from the University of Wisconsin.